New Approaches to Target Bacterial Infections

A multinational pharmaceutical company seeks new antibiotic compounds, adjuvants, and repurposed molecules to combat multidrug-resistant bacterial pathogens. They are particularly interested in agents that have demonstrated antibacterial effects during development for other indications.

Approaches of interest

• Repurposed non-antibiotic drugs 
• Treatments targeting ESKAPE pathogens and emerging pathogens including Candida glabrata, Candida auris, and Aspergillus fumigatus
• Combination therapies that reduce traditional antibiotic adverse effects
• Drugs with improved resistance avoidance and safety profiles

Out of scope:

• For preclinical research, peptides are of limited interest, and biologics and non-molecular approaches are out of scope
• For research in clinical trials and beyond, all modalities are in scope

Developmental stage of interest: Opportunities from preclinical through registration are acceptable.

Email Cameron Sargent, CTTC Licensing Officer, at cameron.sargent@vanderbilt.edu for more information.

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.